India's Drugs Controller General of India (DCGI's) Subject Expert Committee (SEC) recommended granting of permission to conduct Phase III clinical trials for Bharat Biotech's Covid-19 vaccine Covaxin.
The panel added that the recommendation is after assessing data from Phase I & II as well as animal challenge study.
In July, Bharat Biotech had received DCGI nod to conduct phase 1 and 2 clinical trials of an indigenous vaccine for COVID-19.
Covid vaccine latest updates
India-made Covaxin cleared for Phase III trials